Shweta Patel | Women Researcher Award | Pharmaceutical

Published on by Top Pharmaceutical

Women Researcher Award

Shweta Patel — Gokul Global University, India

Shweta Patel
Affiliation Gokul Global University
Country India
Scopus ID 59600471600
Documents 17
Citations 25
h-index 3
Subject Area Pharmaceutical
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8893-3248

Shweta Patel is a researcher associated with Gokul Global University, India, whose documented scholarly record includes pharmaceutical and medicinal chemistry research. Her recent work includes heterocyclic compound synthesis, antimicrobial evaluation, antioxidant studies, and ADME-oriented investigations. The available research record also identifies contributions involving green synthesis and computational assessment of chemical compounds.[1] :contentReference[oaicite:0]{index=0}

Abstract

The research profile of Shweta Patel reflects activity across pharmaceutical chemistry, medicinal chemistry, chemical synthesis, antimicrobial research, and computational drug-development approaches. Available records document studies involving pyran, oxadiazole, thiazolidinone, chromene, quinoline, and related heterocyclic frameworks. Several publications combine synthesis and characterization with biological or ADME-oriented evaluation, providing a multidisciplinary basis for pharmaceutical research.[2]

Keywords

Pharmaceutical Chemistry; Medicinal Chemistry; Drug Discovery; Heterocyclic Chemistry; Antimicrobial Research; Antioxidant Activity; ADME Prediction; Green Synthesis; Chemical Synthesis; Pharmaceutical Innovation.

Introduction

Pharmaceutical research increasingly integrates synthetic chemistry with biological screening and computational approaches to identify compounds with potentially useful pharmacological characteristics. Patel’s documented publications reflect this interdisciplinary pattern, particularly through investigations of heterocyclic derivatives and their antimicrobial or antioxidant properties. The research record also includes studies applying ADME prediction and green synthetic methodologies to pharmaceutical chemistry problems.[3]

Research Profile

The available Scopus-linked record identifies Shweta Patel with Scopus Author ID 59600471600, while the supplied ORCID record identifies 33 works across articles, book chapters, and other research outputs. The documented publication history spans at least 2023–2026 and includes journals such as the Journal of Pharmaceutical Innovation, Russian Journal of General Chemistry, Russian Journal of Organic Chemistry, and related scientific publications.[4]

Research Contributions

A recurring research theme is the design and synthesis of heterocyclic compounds followed by structural characterization and biological evaluation. Recent records include pyrazole–oxadiazole–thioacetamide hybrids, 1,8-naphthyridine–thiazolidinone derivatives, chromene–thiazolidinedione hybrids, and oxadiazole thioacetamide derivatives. These studies demonstrate an emphasis on connecting molecular design with antimicrobial activity and ADME-related assessment.[5]

Publications

The publication portfolio includes recent journal articles and earlier studies in synthetic and pharmaceutical chemistry. Documented examples include work on 2H-pyran derivatives, 1,3,4-oxadiazole derivatives, modified 2-oxochromane compounds, 1,4-dihydropyrano[2,3-c]pyrazoles, and 2-amino-4H-pyrans. The record also contains research on environmental applications of functionalized nanoparticles and pharmaceutical sedation comparisons.[4]

Research Impact

The supplied profile records 17 documents, 25 citations, and an h-index of 3 for the award profile. These metrics provide quantitative indicators of scholarly output and citation activity, although bibliometric values can change as databases are updated. The broader ORCID-linked record indicates additional works and research outputs beyond the selected metrics supplied for this recognition page.[4]

Award Suitability

The documented combination of pharmaceutical chemistry publications, heterocyclic synthesis, antimicrobial evaluation, antioxidant investigations, and ADME-focused research provides a clear scholarly basis for consideration within a pharmaceutical research recognition context. The record contains multiple peer-reviewed journal articles with DOI identifiers, allowing individual publications to be independently located and evaluated. Award consideration should be based on the applicable criteria and verified supporting documentation. [4]

Conclusion

Shweta Patel’s documented research activity encompasses several interconnected areas of pharmaceutical and medicinal chemistry, with particular emphasis on synthetic heterocyclic chemistry and biological evaluation. Her publication record includes recent DOI-indexed studies as well as earlier research on green synthesis and antimicrobial compounds. The available identifiers and publication records provide a basis for further scholarly verification and recognition assessment.

References

 

  1. Elsevier. (n.d.). Scopus author details: Shweta Patel, Author ID 59600471600. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=59600471600
  2. Patel, S. A. (2026). Development of a Novel 1,8-Naphthyridine–Thiazolidinone Derivative: Synthesis, Spectral Characterization, Antimicrobial Profiling, and ADME Prediction. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10426-z
  3. Patel, S. (2026). Structure–Activity Relationship and ADME-Guided Optimization of 4H-Chromene-3-Carbonitrile Derivatives as Promising Antimicrobial Agents. Research Square. https://doi.org/10.21203/rs.3.rs-8718836/v1
  4. Patel, S. (2026). Design and Synthesis of Pyrazole–Oxadiazole–Thioacetamide Hybrids with Antimicrobial and Antioxidant Properties. Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10720-w
  5. Patel, S. (2026). Molecular hybridization approach toward quinoline–thiazolidinedione derivatives: synthesis, DPPH radical scavenging activity, and ADME prediction. Journal of the Iranian Chemical Society. https://doi.org/10.1007/s13738-026-03636-2

Ranjith Kumavath | Drug Repurposing | Research Excellence Award

Published on by Top Pharmaceutical

Research Excellence Award

Ranjith Kumavath
Affiliation Pondicherry University
Country India
Scopus ID 13907540500
Documents 98
Citations 1927
h-index 25
Subject Area Drug Repurposing
Event International Top Pharmaceutical Awards
ORCID 0000-0002-0751-5491

Ranjith Kumavath – Pondicherry University

Ranjith Kumavath of Pondicherry University is a researcher whose scholarly activities are associated with the field of drug repurposing, an interdisciplinary area that integrates pharmaceutical sciences, molecular biology, computational approaches, and translational medicine. This article presents a structured academic overview prepared in the style of a scholarly reference entry, highlighting research profile indicators, publication activity, research impact metrics, and considerations relevant to recognition through the Research Excellence Award at the International Top Pharmaceutical Awards.[1]

Abstract

This academic profile summarizes the scholarly record of Ranjith Kumavath, emphasizing research productivity, citation performance, and contributions within the domain of drug repurposing. Available bibliometric indicators indicate sustained publication activity and measurable scholarly influence through citations and an established h-index. The profile further examines research relevance, interdisciplinary engagement, and potential alignment with the objectives commonly associated with scientific recognition programs and research excellence awards.[1][2]

Keywords

Drug Repurposing; Pharmaceutical Research; Translational Medicine; Research Impact; Bibliometrics; Scopus; Scientific Publications; Citation Analysis; Academic Recognition; Research Excellence.

Introduction

Drug repurposing has emerged as an important strategy in modern pharmaceutical research due to its potential to identify new therapeutic applications for existing compounds while reducing development timelines and associated costs. Researchers working in this area frequently integrate experimental and computational methodologies to evaluate candidate molecules, biological targets, and disease mechanisms. Within this context, the academic record of Ranjith Kumavath reflects engagement with topics relevant to pharmaceutical innovation and translational research.[3]

Research Profile

According to the reported bibliometric indicators, the researcher has accumulated 98 indexed documents, 1,927 citations, and an h-index of 25. These indicators are commonly used to evaluate scholarly productivity and the influence of published work within academic literature.[1]

Research Contributions

The researcher’s contributions are associated with investigations involving therapeutic discovery, molecular mechanisms of disease, computational screening approaches, and the identification of alternative clinical applications for existing pharmaceutical compounds. Such work contributes to broader scientific efforts aimed at improving therapeutic efficiency and expanding treatment opportunities through evidence-based repurposing strategies.[3][2]

Publications

Publication activity constitutes an important component of academic evaluation. The available metrics indicate a substantial body of indexed scholarly work. Representative literature within the broader field of drug repurposing demonstrates the significance of systematic approaches for identifying therapeutic opportunities and validating candidate compounds through experimental and computational frameworks.[3]

Research Impact

Bibliometric indicators suggest that the researcher’s publications have been cited by subsequent scholarly works, indicating engagement with the scientific community and continued relevance within ongoing research discussions. Citation counts and h-index values are commonly considered alongside qualitative assessments when evaluating academic impact and research influence.[1][2]

Award Suitability

Academic awards commonly consider factors such as publication productivity, citation influence, research originality, interdisciplinary engagement, and contributions to scientific advancement. Based on the reported academic indicators, the profile demonstrates characteristics frequently reviewed during recognition processes. Final determinations regarding awards remain subject to the criteria, peer review procedures, eligibility requirements, and evaluation standards established by the awarding organization.[3]

Conclusion

Ranjith Kumavath’s academic profile reflects a documented record of research activity associated with drug repurposing and related pharmaceutical sciences. The available bibliometric indicators demonstrate established scholarly productivity and measurable citation impact. As a reference-style overview, this article summarizes key aspects of research performance, publication activity, and academic visibility relevant to scientific recognition and professional evaluation.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Ranjith Kumavath, Author ID 13907540500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=13907540500
  2. ORCID. (n.d.). ORCID record for Ranjith Kumavath.
    https://orcid.org/0000-0002-0751-5491
  3. P. V., Thomas, N. M., Ranjith, N. K., Muripiti, V., & Banothu, J. (n.d.). Pyrimidine derivatives as anti-HIV agents: Advances and structure–activity relationship insights.
    https://www.sciencedirect.com/science/article/abs/pii/S002228602601639X

Cesar Poli | Biopharmaceutics | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Cesar Poli – Federal University of Rio Grande do Sul, Brazil

Cesar Poli
Affiliation Federal University of Rio Grande do Sul
Country Brazil
Scopus ID 13408393000
Documents 56
Citations 719
h-index 16
Subject Area Biopharmaceutics
Event International Top Pharmaceutical Awards
ORCID 0000-0002-8469-0779

Cesar Poli is a researcher and Associate Professor at the Federal University of Rio Grande do Sul (UFRGS), Brazil. His documented academic profile includes training in Agronomy, Animal Science and Pastoral Science, together with research activity involving sheep production, pasture management, production systems and ruminant nutrition. His ORCID record also identifies continuing academic employment at UFRGS and international research collaborations. [1]

Abstract

The Innovative Research Award profile recognizes the documented scholarly activities of Cesar Poli and presents his research record in an academic context. Available profile information records his association with UFRGS, postgraduate education, international collaborations, publication activity and peer-review participation. His research portfolio includes pasture-based production, sheep management, ruminant nutrition, animal behaviour and plant bioactive compounds. [1]

Keywords

Keywords: Cesar Poli, Innovative Research Award, Biopharmaceutics, Animal Science, Ruminant Nutrition, Pasture Management, Sheep Production, Grazing Systems, Plant Bioactive Compounds, Animal Behaviour, Livestock Research, Pharmaceutical Research.

Introduction

Cesar Poli’s academic career is associated with the Federal University of Rio Grande do Sul, where the ORCID record identifies him as an Associate Professor in Animal Science. His educational history includes an Agronomy degree from UFRGS, postgraduate study in Animal Science/Pastoral Science, and a Ph.D. from Massey University. These qualifications provide the documented foundation for his subsequent research and teaching activities. [1]

Research Profile

The available record describes research centered on the animal-plant interface, sheep production and management, production systems, pasture management, and integrated production and nutrition systems for ruminants. Recent publications address grazing intensity, tropical grass and legume pastures, tannins, lamb performance, animal behaviour and pasture characteristics. [2] [3]

Research Contributions

Poli’s publication record demonstrates sustained investigation of pasture-based livestock systems and nutritional factors affecting ruminant production. His documented studies include work on plant tannins, lamb growth, pasture structure, dietary preference and meat quality. A 2025 publication specifically examined plant tannin for grazing ruminant growth, while another investigated tropical grass and legume pastures grazed by lambs. [3] [4]

Publications

Cesar Poli has published research on pasture management, sheep production, ruminant nutrition, grazing behaviour, and plant bioactive compounds. His documented publications span recent studies and long-term research contributions in animal and pasture science. The research also covers lamb performance, pasture characteristics, dietary preference, and meat quality. His publication record demonstrates sustained scholarly engagement across animal science and related agricultural research areas. [1]

Research Impact

The supplied profile reports 56 documents, 719 citations and an h-index of 16 for the researcher. These bibliometric indicators provide quantitative measures of publication and citation activity, although they should be interpreted alongside disciplinary context, publication type and research collaboration. The ORCID record also documents international projects involving researchers and institutions across several countries. [1]

Award Suitability

For the International Top Pharmaceutical Awards, the Innovative Research Award profile can be considered in relation to the supplied subject classification of Biopharmaceutics and the researcher’s documented scientific record. His publications provide evidence of sustained research activity in biological production systems, nutrition, plant-derived compounds and animal science. Final award assessment should remain subject to the event’s formal evaluation criteria and independent review. [1]

Conclusion

Cesar Poli has a documented academic career at the Federal University of Rio Grande do Sul and a substantial publication record covering pasture management, sheep production, ruminant nutrition, animal behaviour and plant bioactive compounds. His ORCID record supports the chronology of his education, employment, research outputs and peer-review activity. These documented elements provide an academic basis for consideration within an innovation-focused recognition framework. [1]

References

  1. ORCID. (2026). Cesar Poli (0000-0002-8469-0779) – ORCID record. https://orcid.org/0000-0002-8469-0779
  2. Motta, J. H., Poli, C. H. E. C., Irigoyen, L. R., et al. (2026). Patterns of Plant Species Composition Under Different Grazing Intensity in Native Grasslands of Southern Brazil. Rangeland Ecology and Management. https://doi.org/10.1016/j.rama.2025.12.008
  3. Hampel, V. D. S., Poli, C. H. E. C., Tontini, J. F., et al. (2025). Physical and biochemical characteristics of tropical grass and legume pastures grazed by lambs. Grassland Science. https://doi.org/10.1111/grs.12433
  4. Poli, C. H. E. C., Tontini, J. F., Jacondino, L. R., et al. (2025). Plant tannin for grazing ruminant growth. Animal Frontiers. https://doi.org/10.1093/af/vfaf026
  5. Jacondino, L. R., Poli, C. H. E. C., Tontini, J. F., Correa, G., da Silva, I., Nigeliskii, A., Mello, R., Pereira, A., Magalhães, D., & Trindade, M., et al. (2024). Plant Bioactive Compounds of Brazilian Pampa Biome Natural Grasslands Affecting Lamb Meat Quality. Foods, 13(18), 2931. https://doi.org/10.3390/foods13182931

Onwu Daniel Ocha | Drug Discovery | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Onwu, Daniel Ocha
Affiliation University of Cross River State
Country Nigeria
Google Scholar ID n6jcvPsAAAAJ
Documents 9
Citations 2
h-index 1
Subject Area Drug Discovery
Event International Top Pharmaceutical Awards

Onwu Daniel Ocha – University of Cross River State

Onwu Daniel Ocha is a researcher affiliated with the University of Cross River State (UNICROSS), Calabar, Nigeria. His reported scholarly work is associated with computational biology, bioinformatics, drug discovery, network pharmacology, phytochemical investigation, and computational modelling. The supplied Google Scholar record reports nine documents, two citations, and an h-index of one. The profile also identifies computational biology and bioinformatics among the research areas associated with his scholarly activity.

Abstract

Onwu Daniel Ocha’s research profile reflects interdisciplinary activity connecting computational biology and bioinformatics with pharmaceutical and biomedical investigation. His available publication record includes research on phytochemicals, network pharmacology, computational modelling, biological targets, infectious diseases, and therapeutic investigation. These subjects are relevant to modern drug discovery because computational approaches can support the identification of candidate compounds, molecular targets, pathways, and potential mechanisms of action. His research record therefore demonstrates an emerging connection between computational science and pharmaceutical research. [1]

Keywords

Drug Discovery; Computational Biology; Bioinformatics; Network Pharmacology; Computational Modelling; Molecular Docking; Phytochemicals; Drug Target Identification; Systems Biology; Therapeutic Targeting; Pharmaceutical Research; In-silico Research; Biomedical Informatics.

Introduction

Computational biology and bioinformatics have become important components of modern pharmaceutical research. Computational approaches can be used to examine molecular interactions, biological pathways, disease-associated targets, and candidate therapeutic compounds before or alongside laboratory validation. Network pharmacology is particularly useful for studying complex relationships between compounds, proteins, pathways, and disease mechanisms. These approaches can contribute to the prioritization of potential therapeutic candidates and provide hypotheses for subsequent experimental research [1].

Research Profile

The supplied academic profile identifies Onwu Daniel Ocha with the University of Cross River State (UNICROSS), Calabar, Nigeria. His Google Scholar record reports nine documents, two citations, and an h-index of one. The research areas represented in the supplied profile include computational biology and bioinformatics, while the award profile specifically identifies Drug Discovery as the subject area. This combination places his research at the intersection of computational science and pharmaceutical investigation.[3]

Research Contributions

A notable contribution in the supplied publication record is the study titled In-Silico and Network Pharmacology Analysis of Mimosa invisa Phytochemicals against Testicular Inflammation. The work examines phytochemical compounds using computational approaches to investigate their potential relationships with inflammation-associated biological targets. This research direction is relevant to drug discovery because phytochemicals may provide candidate structures for further pharmacological investigation [3].

Publications

The available publication record demonstrates continuing scholarly activity in computational and biomedical research. Listed publications include studies on Mimosa invisa phytochemicals, biosynthesized silver nanoparticles, Terminalia catappa extracts, Allium cepa bioactive compounds, drug-resistant tuberculosis, Tefairia occidentalis phytocompounds, and computational analysis of antiviral targets. The diversity of these topics indicates an interdisciplinary research approach involving computational methods and biological investigation.[3].

Research Impact

The supplied Google Scholar profile reports two citations and an h-index of one. These bibliometric indicators represent the citation activity recorded by the profile at the time of the supplied document and may change as additional publications are indexed and cited. Therefore, citation indicators should be considered together with publication quality, research relevance, collaboration, and scientific contribution when assessing an emerging researcher.[4].

Award Suitability

The award assessment should nevertheless remain evidence-based and should consider the complete research portfolio, verified publication records, originality, methodological quality, scholarly contribution, collaboration, and the official eligibility criteria established by the award organizers. The available profile demonstrates an emerging publication record rather than providing sufficient evidence for unsupported claims of exceptional impact. This distinction maintains a neutral academic approach to recognition[4].

Conclusion

Onwu Daniel Ocha’s documented research profile demonstrates interdisciplinary activity involving computational biology, bioinformatics, drug discovery, network pharmacology, phytochemicals, and systems biology. The supplied record identifies nine documents, two citations, and an h-index of one, while the listed publications demonstrate research activity across several biomedical and pharmaceutical themes. [1].

References

  1. Onwu, D. O., Uraku, O. H., Agbi, M. T., & Uraku, A. J. (2026). In-silico and network pharmacology analysis of Mimosa invisa phytochemicals against testicular inflammation. In Silico Research in Biomedicine, 2, 100274.
    https://doi.org/10.1016/j.insi.2026.100274
  2. Onwu, D., Edun, S., Asuquo, U., & Bajepade, T. I. (2025). Antidiabetic potential of biosynthesized silver nanoparticles with fresh guava leaf. Covenant Journal of Physical and Life Sciences, 13(2), 1–6.
    https://journals.covenantuniversity.edu.ng/index.php/cjpls/article/view/4978
  3. Onwu, D. O., Kayode, D., Oluwatosin, C. E., Chimaobi, N. G., Johnson, O., et al. (2026). Assessing the effects of aqueous extract of Terminalia catappa on immunoglobulins levels in cyclophosphamide induced immunosuppressant Wistar rats. Next Research, 101441.
    https://doi.org/10.1016/j.nexres.2026.101441
  4. Onwu, D. O., Singh, A., Bajpai, Y., Akinlamilo, A. S., Habiganuchi, A., & Ibikunle, F. O. (2025). Host–pathogen interaction mapping in drug-resistant tuberculosis: A systems biology framework for dual therapeutic targeting. Research Square.
    https://doi.org/10.21203/rs.3.rs-7855974/v1
  5. Ahmad, A., Nnenna, A. O., Mamman, S., Nwokoro, C., Bello, A. M., Nseabasi, M. A., Abdulwakiil, M., Okpe, J., Onwu, D. O., Agbi, M., & Idoko, A. (2025). In-silico network pharmacology and computational modelling of bioactive compounds from Allium cepa targeting downstream protein effectors in diabetes. Research Square.
    https://doi.org/10.21203/rs.3.rs-8181479/v1

Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation Global Cosmetic Regulatory Services Pvt Ltd
Country India
Google Scholar N3KRvykAAAAJ
Documents 41
Citations 159
h-index 7
Subject Area Clinical Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

References

  1. Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
  2. Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
  3. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
  4. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
  5. Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 
    https://doi.org/10.1155/2023/3705508

Naglaa Shehab | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Editorial Board Member

Naglaa Shehab — Dubai Medical University
Naglaa Shehab
Affiliation Dubai Medical University
Country United Arab Emirates
Scopus ID 26424069600
Documents 446
Citations 494
h-index 13
Subject Area Drug Discovery and Development
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7514-4055

Naglaa Shehab is recognized for her academic and scientific contributions in pharmaceutical sciences, pharmacognosy, medicinal plant research, and drug discovery investigations. Her scholarly activities demonstrate continuous engagement in phytochemical analysis, natural product development, biological activity assessment, and interdisciplinary pharmaceutical research. Through her editorial and academic involvement at Dubai Medical University, she has contributed to advancing research standards and scientific communication within pharmaceutical sciences.[1] Her work reflects sustained participation in pharmacological innovation, natural medicine evaluation, and translational pharmaceutical studies with relevance to both academic and clinical applications.[2]

Abstract

This academic article presents a structured overview of the editorial and scientific profile of Naglaa Shehab within the field of pharmaceutical sciences. The profile highlights her contributions to pharmacognosy, medicinal plant research, phytochemical investigations, drug-herb interaction studies, and pharmaceutical development. Her research activities demonstrate interdisciplinary collaboration across pharmaceutical chemistry, biological evaluation, and natural product therapeutics. The article additionally reviews selected scientific publications, citation indicators, institutional affiliations, and academic contributions associated with pharmaceutical innovation and evidence-based natural medicine investigations.[1]

Keywords

Pharmacognosy, Drug Discovery, Medicinal Plants, Pharmaceutical Sciences, Natural Products, Phytochemical Investigation, Drug Development, Pharmaceutical Research, Herbal Medicine, Biological Activities

Introduction

Research in pharmaceutical sciences increasingly integrates natural product chemistry, biological evaluation, and translational therapeutic development. Naglaa Shehab has contributed to this multidisciplinary area through research involving medicinal plants, phytochemical profiling, anticancer evaluation, antioxidant studies, and pharmaceutical formulations. Her scientific work spans multiple domains including pharmacognosy, pharmaceutical chemistry, and drug interaction investigations. These activities support broader efforts to identify bioactive compounds and therapeutic applications relevant to healthcare and pharmaceutical innovation.[3]

Research Profile

Naglaa Shehab serves within the academic environment of Dubai Medical University and maintains active involvement in pharmaceutical sciences education and research. Her profile reflects long-term experience in pharmacognosy, medicinal plant analysis, extraction methodologies, and phytochemical characterization. Academic responsibilities have included curriculum development, faculty activities, research coordination, and scientific mentoring. Research interests include herbal-drug interactions, biological evaluation of natural compounds, pharmaceutical formulations, and investigation of medicinal plant constituents with potential therapeutic applications.[1]

  • Research specialization in pharmacognosy and natural products
  • Experience in medicinal plant extraction and phytochemical analysis
  • Editorial and academic participation in pharmaceutical sciences
  • Focus on biological activity evaluation and drug development research

Research Contributions

The research contributions associated with Naglaa Shehab include investigations into anticancer activity, antioxidant mechanisms, hepatoprotective effects, pharmaceutical nanocarriers, herbal formulations, and phytotherapeutic interventions. Her work has examined medicinal plant extracts and their applications in pharmaceutical formulations intended for therapeutic evaluation. Several studies have explored cancer-related mechanisms, drug safety, inflammatory modulation, and natural compounds with potential pharmacological significance.[2][4]

  • Development of phytochemical and natural product formulations
  • Evaluation of anticancer and antioxidant activities
  • Research on medicinal plant-derived therapeutic compounds
  • Studies addressing pharmaceutical efficacy and biological mechanisms

Publications

The publication record of Naglaa Shehab primarily focuses on pharmacognosy, medicinal plants, phytochemical investigations, pharmaceutical formulations, and biological activity evaluation of natural compounds. Her studies commonly explore anticancer activity, antioxidant mechanisms, herbal therapeutics, drug-herb interactions, and pharmaceutical applications of plant-derived bioactive substances. Several publications investigate the therapeutic potential of medicinal extracts through experimental and pharmaceutical approaches, particularly in cancer treatment, inflammatory disorders, hepatoprotective activity, and pharmaceutical nanocarrier systems. The research profile also demonstrates continued involvement in interdisciplinary pharmaceutical sciences and evidence-based natural product development.[3][4]

Research Impact

The research profile of Naglaa Shehab demonstrates measurable scholarly engagement through indexed publications, citation activity, and interdisciplinary pharmaceutical investigations. Her scientific output has addressed medicinal chemistry, herbal medicine, oncology-related pharmaceutical research, and biological evaluation of natural compounds. The documented h-index and citation metrics indicate ongoing academic visibility within pharmaceutical and pharmacognosy-related research communities.[1][5]

Award Suitability

Naglaa Shehab demonstrates suitability for recognition within pharmaceutical and biomedical academic platforms due to her contributions to drug discovery, pharmacognosy, medicinal plant investigations, and pharmaceutical sciences education. Her participation in scientific publishing, interdisciplinary collaborations, and research development aligns with the objectives of international pharmaceutical recognition initiatives. The combination of research productivity, editorial engagement, and pharmaceutical innovation supports her relevance to academic award and editorial board recognition programs.[5]

Conclusion

The academic profile of Naglaa Shehab reflects continued engagement in pharmaceutical sciences, medicinal plant investigations, and natural product research. Her scholarly contributions encompass pharmaceutical formulations, phytochemical analysis, biological evaluation, and interdisciplinary healthcare applications. Through editorial participation, scientific publications, and pharmaceutical research activities, she contributes to ongoing developments within drug discovery and pharmaceutical innovation.[1][2]

References

  1. ORCID. (2026). Naglaa Shehab ORCID profile and academic activities. ORCID Registry.https://orcid.org/0000-0002-7514-4055
  2. Elsevier. (n.d.). Scopus author details: Naglaa Shehab, Author ID 26424069600. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26424069600
  3. Khalifa, A., Shehab, N.G., et al. (2026). Development of Phyllanthus emblica Extract-Loaded Niosomes for Cancer Treatment: Formulation and In Vitro Evaluation. Pharmaceuticals.DOI:https://doi.org/10.3390/ph19040582
  4. Bou Malhab, L.J., Shehab, N.G., et al. (2023). Potential Anticancer Properties of Calotropis procera: An Investigation on Breast and Colon Cancer Cells. Heliyon.DOI:https://doi.org/10.1016/j.heliyon.2023.e16706
  5. Anbar, H.S., El Wakil, A., Shehab, N.G., et al. (2024). The wound healing and hypoglycemic activates of date palm (Phoenix dactylifera) leaf extract and saponins in diabetic and normal rats. PLOS ONE.
    DOI: https://doi.org/10.1371/journal.pone.0308879

Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on by Top Pharmaceutical

Excellence in Research Award


Aniela Montserrat Silva Nolasco

Universidad de Castilla-La Mancha, Spain


Aniela Montserrat Silva Nolasco
Affiliation Universidad de Castilla-La Mancha
Country Spain
Scopus ID
57221107566
Documents 21
Citations 23
h-index 2
Subject Area Pharmaceutical Chemistry
Event International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
  2. ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
  3. Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
  4. Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
  5. Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Naglaa Shehab| Drug Discovery and Development | Research Excellence Award

Professor | Dubai Medical University | United Arab Emirates 

Prof. Naglaa Gamil Shehab is a Professor of Pharmaceutical Sciences at Dubai Medical University, specializing in pharmacognosy, phytochemistry, medicinal plants, and complementary medicine. She holds advanced degrees in pharmacognosy with a strong foundation in phytochemical research and natural product analysis. Her academic career spans progressive roles from teaching and research to senior professorship and academic leadership, including key responsibilities in curriculum development and coordination of multidisciplinary pharmaceutical courses. Her research focuses on the pharmacognostical and phytochemical investigation of medicinal plants, contributing to the validation of natural therapies and alternative medicine through scientific methodologies. With a notable citation record, consistent publication output, and measurable scholarly impact, she has established herself as a recognized contributor to pharmaceutical sciences. She is actively engaged in academic service through editorial contributions, professional memberships, and mentorship of emerging researchers, reflecting sustained commitment to advancing research quality and innovation in pharmacognosy and related disciplines.

Citation Metrics (Google Scholar)

779
600
400
200
0

779

18

14

Citations

i10-index

h-index


Top 5 Featured Publications

 

Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Published on by Top Pharmaceutical

Dr. Hareesh Nair | Drug Discovery and Development | Outstanding Scientist Award

Texas Tech University Health Science Center | United States

Dr. Hareesh B. Nair, Ph.D., is a distinguished biochemist and translational scientist whose career spans academia, biotechnology innovation, and advanced research leadership. He completed his academic training in life sciences and biochemistry in India, followed by specialized research fellowships in oxidative lipidomics and hormonal carcinogenesis at leading U.S. institutions. These early experiences laid the foundation for his lifelong commitment to understanding disease mechanisms and developing targeted therapeutic solutions.Dr. Nair’s professional journey reflects a rare blend of deep scientific expertise and strategic research leadership. Over the course of his career, he has held progressive roles ranging from instructor and assistant professor to senior scientist, director, and senior director of translational research and external innovation. His contributions at the University of Texas Health Science Center at San Antonio and the Texas Biomedical Research Institute significantly advanced the fields of breast cancer biology, hormonal carcinogenesis, melanoma signaling pathways, endometriosis, uterine fibroids, and targeted drug delivery. His work also includes pioneering estrogen-dependent cancer research, mechanistic studies on aromatase pathways, development of innovative cancer detection strategies, and creation of non-human primate models for reproductive disorders.At Evestra, Inc., Dr. Nair led multidisciplinary teams driving the translational development of oncology and women’s health therapeutics. He spearheaded multiple preclinical programs, established strategic collaborations, guided biomarker discovery, contributed to regulatory submissions, and supported business development through scientific due diligence. His leadership also resulted in the advancement of first-in-class and best-in-class therapeutic candidates, expansion of oncology pipelines, and successful acquisition of non-dilutive federal funding. His contributions include numerous publications, patents, and project management of large-scale contraceptive development initiatives supported by major global health foundations.In his current academic role at Texas Tech University Health Sciences Center El Paso, Dr. Nair is establishing a cutting-edge research laboratory at the chemistry–biology interface. His group focuses on identifying novel drug targets, decoding disease mechanisms, and transforming molecular insights into preclinical therapeutic strategies for cancers and other complex diseases. He remains deeply engaged in collaborative clinical and translational research, particularly in gynecologic oncology, triple-negative breast cancer, ovarian cancer, and endometrial cancer. His expertise also extends to long-acting contraceptive technologies, anti-HIV formulations, and experimental therapeutics for endometriosis and uterine fibroids.Beyond research, Dr. Nair has served extensively as a scientific review officer, facilitating numerous peer-review panels for federal biomedical research programs. His work has been recognized through multiple competitive honors, travel awards, and scientific achievement distinctions. With a strong commitment to innovation, mentorship, and multidisciplinary collaboration, Dr. Hareesh B. Nair continues to shape the future of translational medicine through impactful research, strategic leadership, and unwavering dedication to improving patient health outcomes.

Profile: Orcid

Featured Publications

Aller, E. J., Nair, H. B., Vadlamudi, R. K., & Viswanadhapalli, S. (2025). Significance of midkine signaling in women’s cancers: novel biomarker and therapeutic target. International Journal of Molecular Sciences, 26(10), 4809.

Blankenship, L., Pratap, U. P., Yang, X., Liu, Z., Altwegg, K. A., Santhamma, B., … Lai, Z. (2022). Inhibition of LIFR blocks adiposity‑driven endometrioid endometrial cancer growth. Cancers, 14(21), 5400.

Nair, H. B., Ford, A., Dick, E. J., Jr., Hill, R. H., Jr., & VandeBerg, J. L. (2014). Modeling sunscreen‑mediated melanoma prevention in the laboratory opossum (Monodelphis domestica). Pigment Cell & Melanoma Research, 27(5), 822‑830.

Nickisch, K., Nair, H. B., Kesavaram, N., Das, B., Garfield, R., Shi, S. Q., … Edwards, D. P. (2013). Synthesis and antiprogestational properties of novel 17‑fluorinated steroids. Steroids, 78(9), 895‑902.

Bhaskaran, S., Dileep, K. V., Deepa, S. S., Sadasivan, C., Klausner, M., Krishnegowda, N. K., … Nair, H. B. (2013). Gossypin as a novel selective dual inhibitor of V‑RAF murine sarcoma viral oncogene homolog B1 and cyclin‑dependent kinase 4 for melanoma. Molecular Cancer Therapeutics, 12(4), 567‑576.

Budrys, N. M., Nair, H. B., Liu, Y. G., Kirma, N. B., Binkley, P. A., Kumar, S., … Tekmal, R. R. (2012). Increased expression of macrophage colony‑stimulating factor and its receptor in patients with endometriosis. Fertility and Sterility, 97(5), 1159‑1165.e1.

Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Vijay Kumar | Drug Discovery and Development | Editorial Board Member

Dr B R Ambedkar NIT Jalandhar, India

Assoc. Prof. Dr. Vijay Kumar is a distinguished researcher, academician, and innovator in the fields of artificial intelligence, machine learning, biomedical informatics, cybersecurity, image processing, and computational intelligence. Over the course of his career, he has established himself as a prolific contributor whose research bridges advanced computational theories with real-world applications, particularly in healthcare, pandemic intelligence, medical imaging, network security, and autonomous systems. His academic journey is defined by a commitment to solving high-impact global challenges through intelligent algorithms, deep learning frameworks, optimization strategies, and secure data-driven technologies.Dr. Vijay Kumar’s scholarly work reflects exceptional depth and diversity. He has authored impactful publications in leading journals such as IEEE Transactions on Vehicular Technology, IEEE Journal of Biomedical and Health Informatics, Vaccine, Artificial Intelligence Review, Archives of Computational Methods in Engineering, Multimedia Tools and Applications, Computers in Biology and Medicine, and Biomedical Signal Processing and Control. His research spans a broad spectrum—from deepfake detection, autonomous vehicle visibility enhancement, multi-objective optimization, and cybersecurity frameworks, to intelligent diagnostic models for COVID-19, breast cancer, cervical cancer, and other critical diseases. His studies on advanced metaheuristic algorithms, chaotic encryption systems, drug synergy prediction, air-quality forecasting, and big healthcare data security have contributed significantly to modern computational science. A visionary in interdisciplinary AI, Dr. Kumar has collaborated extensively with international researchers, producing high-impact work on deep neural networks, generative adversarial models, hybrid optimization techniques, multimodal medical imaging, and cloud-based encryption systems. His contributions to pandemic preparedness, especially ML-driven vaccine development roadmaps and intelligent screening systems, highlight his dedication to translating technology into meaningful societal outcomes.He is also recognized for designing innovative algorithms such as lightweight NIDS architectures, evolutionary visibility restoration models, customized dehazing networks, and novel feature-selection optimizers. His body of work has become a reference point for emerging scholars in computer science, health informatics, and computational engineering.Dr. Vijay Kumar continues to lead transformative research, mentor young scientists, and contribute to global scientific advancement through his extensive publication record, collaborative projects, and commitment to innovation. His enduring academic excellence and forward-looking approach place him among the most influential researchers driving the future of intelligent systems and healthcare-focused artificial intelligence.

Profile: Google Scholar

Featured Publications

Katoch, S., Chauhan, S. S., & Kumar, V. (2020). A Review on Genetic Algorithm: Past, Present, and Future. Multimedia Tools and Applications, 52, 5252.

Dhiman, G., & Kumar, V. (2019). Seagull optimization algorithm: Theory and its applications for large‑scale industrial engineering problems. Knowledge‑Based Systems, 165, 169‑196.

Dhiman, G., & Kumar, V. (2017). Spotted Hyena Optimizer: A Novel Bio‑inspired based Metaheuristic Technique for Engineering Applications. Advances in Engineering Software, 114, 48‑70.

Dhiman, G., & Kumar, V. (2018). Emperor Penguin Optimizer: A Bio‑inspired Algorithm for Engineering Problems. Knowledge‑Based Systems, 159, 20‑50.

Singh, D., Kumar, V., Vaishali, & Kaur, M. (2020). Classification of COVID‑19 patients from chest CT images using multi‑objective differential evolution–based convolutional neural networks. European Journal of Clinical Microbiology & Infectious Diseases, 39, 1379‑1389.

Jaiswal, A., Gianchandani, N., Singh, D., Kumar, V., & Kaur, M. (2020). Classification of the COVID‑19 infected patients using DenseNet201 based deep transfer learning. Journal of Biomolecular Structure and Dynamics, 73, 1‑?.

Dhiman, G., Garg, M., Nagar, A., Kumar, V., & Dehghani, M. (2020). A Novel Algorithm for Global Optimization: Rat Swarm Optimizer. Journal of Ambient Intelligence and Humanized Computing, 5, 12‑?.

Das, N. N., Kumar, N., Kaur, M., Kumar, V., & Singh, D. (2020). Automated deep transfer learning‑based approach for detection of COVID‑19 infection in chest X‑rays. IRBM, 4, 25‑?.

Kaur, M., & Kumar, V. (2020). A comprehensive review on image encryption techniques. Archives of Computational Methods in Engineering, 27(1), 390.